Skip to main content
SpringerLink
Log in

Taxane-based adjuvant chemotherapy in node positive, early stage Turkish breast cancer patients

  • Research Article
  • Published:
Central European Journal of Medicine

Abstract

Adjuvant chemotherapy decreases the risk of breast cancer recurrence in patients with breast cancer. In addition, it increases the rate of survival. Therefore, various chemotherapy regimens are administered in the treatment of breast cancer. The efficacy of taxane-based adjuvant chemotherapies has been demonstrated in various trials. This trial was designed to retrospectively evaluate the efficacy of taxane-based chemotherapies in lymph node-positive, early-stage Turkish breast cancer patients. 29 patients receiving TAC regimen and 29 patients receiving AC+P regimen were evaluated. 6 courses of TAC regimen were administered every 3 weeks (docetaxel 75 mg/m2, doxorubicine 50 mg/m2, cyclophosphamide 500 mg/m2). The other patient group was administered AC+P regimen (4 courses of doxorubicin 60mg/m2, cyclophosphamide 600 mg/m2 combination every 2 weeks, followed by paclitaxel 175 mg/m2 for 4 courses every 2 weeks). The 1-year, 2-year and 3-year disease-free survival (DFS) rates were 96.3%, 81.1% and 72.8% respectively. No significant difference was detected in DFS between premenopausal and postmenopausal patients on the taxane regimen (p=0.82). There was no significant difference in DFS between estrogen or progesterone receptor positive and negative patients (p=0.46). Disease-free survival of patients receiving TAC and AC+P adjuvant chemotherapy regimen was compared. The follow-up period of patients on AC+P chemotherapy was longer than those receiving TAC (AC+P mean 38.6±12.8 months, TAC mean 17.1±5.4 months). No significant difference was observed upon evaluation of both treatment arms with respect to DFS (p=0.92). In conclusion, this trial once more demonstrated that taxane-based adjuvant chemotherapy was effective and safe in lymph node-positive, early-stage Turkish breast cancer patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin. 2008;58(2):71–96

    Article  PubMed  Google Scholar 

  2. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687–1717

    Article  Google Scholar 

  3. Hudis C. The best use of adjuvant chemotherapy: New drugs and new use of old drugs. The Breast 2005;14: 570–575

    Article  PubMed  Google Scholar 

  4. Ring AE, Ellis A. Taxanes in the treatment of early breast cancer. Cancer Treat Rev 2005;31: 618–627

    Article  PubMed  CAS  Google Scholar 

  5. Bria E, Nistico C, Cuppone F, Carlini P, Ciccarese M, Milella M, Natoli G, Terzoli E, Cognetti F, Giannarelli D. Benefit of taxanes as adjuvant chemotherapy for early breast cancer. Cancer 2006;106:2337–2344

    Article  PubMed  CAS  Google Scholar 

  6. Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003;21:976–983

    Article  PubMed  CAS  Google Scholar 

  7. Mamounas EP, Bryant J, Lembersky B, et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node positive breast cancer: results from NSABP B-28. J Clin Oncol 2005,23: 3686–3696

    Article  PubMed  CAS  Google Scholar 

  8. Martin M, Pienkowski T, Mackey J et al. Adjuvant docetaxel for node positive breast cancer. N Engl J Med 2005;352:2302–2313

    Article  PubMed  CAS  Google Scholar 

  9. Crown JP, Francis P, Di Leo A, et al. Docetaxel (T) given concurrently with or sequentially to anthracycline-based (A) adjuvant therapy (adjRx) for patients (pts) with node-positive (N+) breast cancer (BrCa), in comparison with non-T adjRx: First results of the BIF-2-98 Trial at 5-years median follow-up (MFU). Proc Am Soc Clin Oncol 2006; 24: Abstract 519

  10. Sparano JA, Wang M, Martino S, et al. Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node positive of high-risk node-negative breast cancer: results of North American Breast Cancer Intergroup Trial E1199. Breast Cancer Res Treat. 2005;94(suppl 1). Abstract 48

  11. Piedbois P, Serin D, Priou F, Laplaige P, Greget S, Angellier E, Teissier E, Berdah JF, Fabbro M, Valenza B, Herait P, Jehl V, Buyse M. Dose-dense adjuvant chemotherapy in node positive breast cancer: followed by epirubicine/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study. Annals of Oncology 2007;18:52–57

    Article  PubMed  CAS  Google Scholar 

  12. Berry DA, Cirrincione C, Henderson IC, et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006;12:1658–1667

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Oncology, Izmir Research and Training Hospital, 35360, Bozyaka, Izmir, Turkey

    Ahmet Alacacioglu

  2. Clinic of 1.General Surgery, Izmir Research and Training Hospital, 35360, Bozyaka, Izmir, Turkey

    Baha Zengel & Ali Galip Denecli

Authors
  1. Ahmet Alacacioglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Baha Zengel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ali Galip Denecli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ahmet Alacacioglu.

About this article

Cite this article

Alacacioglu, A., Zengel, B. & Denecli, A.G. Taxane-based adjuvant chemotherapy in node positive, early stage Turkish breast cancer patients. cent.eur.j.med 4, 454–458 (2009). https://doi.org/10.2478/s11536-009-0075-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2478/s11536-009-0075-9

Keywords

Search

Navigation